Academy

Catherine Wu, MD - Clonal Heterogeneity in CLL and Opportunities for Immune Targeting

Matthew Davids, MD - How I Choose Which Frontline Treatment I Use in Which Patient

Alessandra Ferrajoli, MD - Interesting/Unusual Cases in CLL

Panel Discussion

John Allan, MD - Small Molecule Combinations

Neil Kay, MD - MRD in CLL, is it Ready for Use in Practice?

Nicole Lamanna, MD - Debate: BTKi or VenG for Non-17p Deleted Patients with Unmutated IGHV: BTKi

Mazyar Shadman, MD - Debate: BTKi or VenG for Non-17p Deleted Patients with Unmutated IGHV: VenG

Panel Discussion

David Maloney, MD - CAR-T in CLL

Catherine Coombs, MD - Non-covalent BTKi

Adam Kittai, MD - Richter’s Syndrome, What’s on the Horizon?

Panel Discussion

Danielle Brander, MD - Debate: MRD + at 1 Year of VenG: Stop Therapy or Continue?: Pro Stopping

Alexey Danilov, MD - Debate: MRD + at 1 Year of VenG: Stop Therapy or Continue?: Con Stopping

Sameer Parikh, MD - Monoclonal B-cell Lymphocytosis – What’s New in 2024?

John Allan, MD - CLL, Next Questions

Panel Discussion

Christopher Flowers, MD - Novel Strategies for First-line Treatment of DLBCL

Paolo Strati, MD - Strategies for Identifying and Addressing Poor-risk, Follicular Lymphoma in the First-line

John P. Leonard, MD - What’s Now and What’s Next for First-line Therapy in MCL

Panel Discussion

Mark Roschewski, MD - Cell-free DNA Assessment

Jordan S. Goldstein, MD - Optimizing ctDNA Limits of Detection for DLBCL during First Line Therapy

Paolo Strati, MD - Application of cfDNA Technologies in FL

Dai Chihara, MD - Debate: Bringing Molecular Testing to First-line Therapy in DLBCL: Test the Test - Can We Do Molecular Testing in the Real World?

Sandeep Dave, MD - Debate: Bringing Molecular Testing to First-line Therapy in DLBCL: Bringing DuoSeq to Practice

Panel Discussion